title: Recent Advances in Targeted Therapy for Glioma.
abstract: Gliomas are the most common primary malignant brain tumors, which have a universally fatal outcome. Current standard treatment for glioma patients is surgical removal followed by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the tumor progression and provide additional methods for individual treatment of glioma patients. By studying the initiation and maintenance of glioma, studies focused on the targets of tyrosine kinase receptors including EGFR, PDGFR and other crucial signal pathways such as PI3K/AKT and RAS/RAF/MAPK pathway. Furthermore, recent advances in targeting immunotherapy and stem cell therapy also brought numerous strategies to glioma treatment. This article reviewed the researches focused on the advanced strategies of various target therapies for improving the glioma treatment efficacy, and discussed the challenges and future directions for glioma therapy.
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.|Neurosurgical Institute, Heilongjiang Academy of Medical Science, Harbin, China.|Neuroscience Institute, Sino-Russian Medical Research Center, Harbin, China.|Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.|Neurosurgical Institute, Heilongjiang Academy of Medical Science, Harbin, China.|Neuroscience Institute, Sino-Russian Medical Research Center, Harbin, China.|Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Jinquan
authors.initials: J
authors.lastname: Cai
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.|Neurosurgical Institute, Heilongjiang Academy of Medical Science, Harbin, China.|Neuroscience Institute, Sino-Russian Medical Research Center, Harbin, China.|Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Chuanlu
authors.initials: C
authors.lastname: Jiang
mesh_terms: D000477:Alkylating Agents / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D005910:Glioma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism
chemical_list: D000477:Alkylating Agents; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases
keywords: Glioma; Immunotherapy; cell signal transduction pathway; clinical trials; glioma stem cell; targeted therapy